Back to search

Article

The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters

2022-02-09

Abstract excerpt

A well-tolerated and cost-effective oral drug that blocks SARS-CoV-2 growth and dissemination would be a major advance in the global effort to reduce COVID-19 morbidity and mortality. Here, we show that the oral FDA-approved drug nitazoxanide (NTZ) significantly inhibits SARS-CoV-2 viral replication and infection in different primate and human cell models including stem cell-derived human alveolar epithelial type...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bf4bfa4d-ad68-5da1-bf4f-1be89fbbda90
DOI
10.1101/2022.02.08.479634
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamstersDOI 10.1101/2022.02.08.479634
Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variantSemantic proximity
Orally administered epeleuton inhibits SARS-CoV-2 viral load, replication and pathology in the Syrian Hamster modelSemantic proximity
Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19Semantic proximity
Annual SZ® A Novel Formulation For COVID-19 Therapy Clinical Trial StudiesSemantic proximity
Inhibitors of SARS-CoV‑2 Entry: Current and Future OpportunitiesSemantic proximity
The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoproteinSemantic proximity
The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoproteinSemantic proximity
Preclinical and Clinical Study of Efficacy of NAOQ19 against SARS-COV2: A Comprehensive EvaluationSemantic proximity
Differential Immunometabolism and Tissue Responses to Delta and Omicron SARS-CoV-2 Variants in Golden Syrian Hamster ModelsSemantic proximity
Differential Immunometabolism and Tissue Responses to Delta and Omicron SARS-CoV-2 Variants in Golden Syrian Hamster ModelsSemantic proximity
Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 modelSemantic proximity
Bromhexine Prophylaxis and Pharmacologically Attenuated Natural Immunization: A New Paradigm of Host-Directed Modulation of SARS-CoV-2 and Influenza Virus InfectionsSemantic proximity
Select a neighboring publication to make it the new centre.